Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial
Advances in Therapy · 2025
DOI: 10.1007/s12325-025-03393-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Milos Jesenak und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Jessenius Faculty of Medicine in Martin, University Hospital in Martin, Comenius University in Bra…. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Dietary Supplements, Vitamin D, Zinc. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pleuran s.r.o., Slovak Academy of Sciences.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
INTRODUCTION: Recurrent respiratory tract infections (RRTIs) are common in childhood and impose substantial socioeconomic burden. β-Glucans, particularly pleuran from Pleurotus ostreatus, demonstrate immunomodulatory properties through the pathogen-associated molecular pattern receptor interactions. This study evaluated a novel chewable pleuran-based supplement with vitamin D and zinc for preventing respiratory infections in children with RRTIs. METHODS: This international, multicentre, randomised, double-blind, placebo-controlled trial enrolled 249 children with RRTIs from Slovakia, Czech Republic, and Serbia. Participants received either pleuran-based supplement (IMG® with vitamin D and zinc) or active placebo (vitamin D and zinc) for 3 months during respiratory infection season (October-March). Primary endpoint was total respiratory tract infections (RTIs). Secondary endpoints included RTI subtypes, RTI duration, missed school days, and safety evaluations. RESULTS: In total, 217 children completed the study (104 active, 113 placebo). The active group experienced significantly fewer total RTIs versus placebo (2.35 ± 1.25 vs. 2.77 ± 1.78; P = 0.042), representing 15.2% reduction over 3 months. Common cold episodes were reduced by 18.6% (1.53 ± 1.22 vs. 1.88 ± 1.25; P = 0.040). Effects were pronounced in children over 6 years (P = 0.026 for total RTIs; P = 0.005 for common cold) and evident after the first month (P = 0.037). Tonsillopharyngitis showed significant reductions in frequency (P = 0.003) and duration (P = 0.009). Post hoc analysis of children enrolled at respiratory season onset confirmed significant reductions in common cold frequency (P = 0.004) and duration (P = 0.023). The supplement demonstrated excellent tolerability with 98.7% compliance and only mild adverse events. CONCLUSION: Chewable pleuran-based supplement with vitamin D and zinc significantly reduced respiratory tract infections in children with RRTIs, with rapid onset and favourable safety profile, demonstrating therapeutic potential in this vulnerable population. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT06974747.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Adolescent Medicine, Jessenius Faculty of Medicine in Martin, University Hospital in Martin, Comenius University in Bratislava, Martin, Slovakia.
- Institute of Clinical Immunology and Medical Genetics, Jessenius Faculty of Medicine in Martin, University Hospital Martin, Comenius University in Bratislava, Martin, Slovakia.
- PRO BABY, Ltd., Bratislava, Slovakia.
- Department of Paediatrics, Agel Hospital, Ostrava-Vítkovice, Ostrava, Czech Republic.
- Clinic of Allergy and Clinical Immunology, Clinical Centre of Serbia, Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Förderung
- Pleuran s.r.o.
- Slovak Academy of Sciences
Zitieren
APA
Jesenak, M., Prokopova, E., Bozensky, J., Bonaci-Nikolic, B., Milosevic, K., Stankovic, K., Ostojic, O., Zivkovic, Z., Diamant, Z., Kunc, P., Janeczek, K., & Majtan, J. (2025). Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial. Advances in Therapy. https://doi.org/10.1007/s12325-025-03393-3
Vancouver
Jesenak M, Prokopova E, Bozensky J, Bonaci-Nikolic B, Milosevic K, Stankovic K, et al. Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial. Advances in Therapy. 2025. doi:10.1007/s12325-025-03393-3
BibTeX
@article{Jesenak2025,
author = {Jesenak, Milos and Prokopova, Elena and Bozensky, Jan and Bonaci-Nikolic, Branka and Milosevic, Katarina and Stankovic, Katarina and Ostojic, Olivera and Zivkovic, Zorica and Diamant, Zuzana and Kunc, Peter and Janeczek, Kamil and Majtan, Juraj},
title = {Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03393-3}
}
EUVIMED